News

Gilead Sciences, Inc. and Merus N.V. announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific…
Read More...

Janssen-Cilag International NV, a Johnson & Johnson company, announced the submission of a Type II variation application to the European Medicines Agency (EMA). The submission is…
Read More...

Sandoz, the global leader in generic and biosimilar medicines, announced that the US Food and Drug Administration (FDA) approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz),…
Read More...

Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of…
Read More...

FogPharma, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently available medicines using its Helicon…
Read More...

The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in two types of…
Read More...

AbbVie Inc. and OSE Immunotherapeutics SA announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in…
Read More...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, announced that the U.S. Food and Drug…
Read More...

Gilead Sciences, Inc. announced the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir…
Read More...

Telix announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in…
Read More...

Bristol Myers Squibb announced that it has successfully completed its acquisition of RayzeBio, Inc. With the completion of the acquisition, RayzeBio shares have ceased trading on the…
Read More...

Amneal Pharmaceuticals, Inc. announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group, for IPX203 in the European Union,…
Read More...

Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or…
Read More...

AstraZeneca announced the successful completion of the acquisition of Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing innovative cell…
Read More...

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with…
Read More...

AbbVie Inc. and Tentarix Biotherapeutics announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in…
Read More...

Ligand Pharmaceuticals Incorporated announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and…
Read More...

WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical…
Read More...

Charles River Laboratories International, Inc. announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on…
Read More...

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to…
Read More...